Preliminary Results for the Year Ended 31 December 2023
April 19, 2024 08:00 ET
|
Biodexa Pharmaceuticals PLC
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 16, 2024 16:30 ET
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
April 16, 2024 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024 07:02 ET
|
Ocugen
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen,...
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
April 01, 2024 17:43 ET
|
Ocugen
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
March 18, 2024 14:37 ET
|
PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
March 07, 2024 15:23 ET
|
PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer...
Biopharmaceutical Fermentation Systems Market Projected to Reach USD 52.6 billion by 2031, with a CAGR of 9.5%: Report by Transparency Market Research Inc.
March 01, 2024 01:32 ET
|
Transparency Market Research
Wilmington, Delaware, United States, March 01, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biopharmaceutical fermentation systems market is projected to grow at a CAGR of...